Anuh Pharma has rallied 20% to 245 on the BSE in intra-day trade after the company said World Health Organisation (WHO) Geneva approved the manufacturing site in district Thane, Boisar, Maharashtra.
“The company’s Maharashtra site found in compliance to WHO good manufacturing practices (GMPs) for Pyrazinamide APIMF158 and Sulfadoxine APIMF234 active pharmaceutical ingredients (APIs),” Anuh Pharma said in a release.
At 01:38 pm; the stock was up 13% at Rs 231, the top gainer among the S&P BSE Smallcap index. Around 130,000 shares changed hands on the counter against an average 2,844 shares that were traded daily in past two weeks on the BSE.
Latest posts by savita thakur (see all)
- CDSCO releases Risk classification of Medical Devices and IVDs - November 8, 2017
- Bodhtree completes project for Medical Council of India - November 5, 2017
- Daiichi versus Ranbaxy: Singapore SC allows Harish Salve to represent the case - November 2, 2017